Studies on the Response of Patients with Classic Hemophilia to Transfusion with Concentrates of Antihemophilic Factor
Authors:
- Bruce BennettBBBruce Bennett
- Oscar D. RatnoffOROscar D. Ratnoff
Open Access
- 1 October 1972
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 51 (10) , 2593-2596
Abstract
Antihemophilic factor (AHF, factor VIII) levels were measured by a standard coagulation method and by an immunologic technique before and after infusion of AHF concentrates into patients with classic hemophilia. After infusion of AHF concentrates, the half-life of the AHF procoagulant (i.e., clot-promoting) activity varied from 12 to 14 hr, whereas that of the antigen ranged from 24 to 40 hr. The half-life of the antigen was similar in patients with and without circulating anticoagulants to AHF. The data are compatible with the suggestion that the antigen may be carried on a precursor molecule which the patient with hemophilia produces but cannot convert to the functional clot-promoting agent. Other explanations of the observations are, however, recognized.Keywords
This publication has 5 references indexed in Scilit:
- Immunologic Studies in von Willebrand's DiseaseJournal of Clinical Investigation, 1972
- Factor VIII Detection by Hemagglutination Inhibition: Hemophilia A and von Willebrand's DiseaseScience, 1971
- Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag SystemNew England Journal of Medicine, 1965
- The Fate of Prothrombin and Factors VIII, IX and X Transfused to Patients Deficient in these FactorsBritish Journal of Haematology, 1963
- THE SURVIVAL OF FACTOR VIII (ANTIHEMOPHILIC GLOBULIN) AND FACTOR IX (PLASMA THROMBOPLASTIN COMPONENT) IN NORMAL HUMANS*Journal of Clinical Investigation, 1963